Evaxion End Period Cash Flow from 2010 to 2024

EVAX Stock  USD 1.54  0.12  7.23%   
Evaxion Biotech End Period Cash Flow yearly trend continues to be fairly stable with very little volatility. End Period Cash Flow will likely drop to about 5.3 M in 2024. During the period from 2010 to 2024, Evaxion Biotech End Period Cash Flow regression line of annual values had r-squared of  0.06 and arithmetic mean of  9,235,123. View All Fundamentals
 
End Period Cash Flow  
First Reported
2010-12-31
Previous Quarter
5.6 M
Current Value
5.3 M
Quarterly Volatility
6.6 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Evaxion Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Evaxion Biotech's main balance sheet or income statement drivers, such as Interest Income of 1.4 M, Depreciation And Amortization of 330.1 K or Interest Expense of 1 M, as well as many indicators such as Price To Sales Ratio of 206, Dividend Yield of 0.0 or Days Sales Outstanding of 4.3 K. Evaxion financial statements analysis is a perfect complement when working with Evaxion Biotech Valuation or Volatility modules.
  
Check out the analysis of Evaxion Biotech Correlation against competitors.

Latest Evaxion Biotech's End Period Cash Flow Growth Pattern

Below is the plot of the End Period Cash Flow of Evaxion Biotech AS over the last few years. It is Evaxion Biotech's End Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Evaxion Biotech's overall financial position and show how it may be relating to other accounts over time.
End Period Cash Flow10 Years Trend
Pretty Stable
   End Period Cash Flow   
       Timeline  

Evaxion End Period Cash Flow Regression Statistics

Arithmetic Mean9,235,123
Geometric Mean8,173,046
Coefficient Of Variation71.54
Mean Deviation3,627,151
Median7,433,000
Standard Deviation6,606,885
Sample Variance43.7T
Range26.9M
R-Value0.24
Mean Square Error44.2T
R-Squared0.06
Significance0.38
Slope361,207
Total Sum of Squares611.1T

Evaxion End Period Cash Flow History

20245.3 M
20235.6 M
202213.2 M
202132.2 M
20205.8 M
20199.6 M

About Evaxion Biotech Financial Statements

Evaxion Biotech investors use historical fundamental indicators, such as Evaxion Biotech's End Period Cash Flow, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Evaxion Biotech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
End Period Cash Flow5.6 M5.3 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Evaxion Stock Analysis

When running Evaxion Biotech's price analysis, check to measure Evaxion Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evaxion Biotech is operating at the current time. Most of Evaxion Biotech's value examination focuses on studying past and present price action to predict the probability of Evaxion Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evaxion Biotech's price. Additionally, you may evaluate how the addition of Evaxion Biotech to your portfolios can decrease your overall portfolio volatility.